Biopharma Companies in Europe

Eurofins Genomics is a leading international provider of genomic services, specializing in next-generation sequencing, genotyping, and gene expression analysis. Based in Ebersberg, Germany, we support a diverse range of sectors including pharmaceuticals, diagnostics, agriculture, and research. As part of the Eurofins Scientific Group, a global life science leader with a presence in 61 countries, we leverage our extensive expertise and cutting-edge technology to deliver tailored genomic solutions. Our commitment to quality and precision, combined with our ISO 17025 accreditation, ensures reliable and impactful results for our clients worldwide. We offer a comprehensive portfolio of products and services, from custom oligonucleotide synthesis and gene synthesis to advanced sequencing and bioinformatics analysis, empowering scientific discovery and innovation.

TEK Optima Research is a leading provider of advanced imaging systems and AI-powered software solutions, based in Wimborne, Dorset, UK.

We specialize in designing and manufacturing high-performance hardware and innovative DeepInsight cell fingerprinting technology for the Biotech, Medical, and related microscopic imaging industries. Our solutions enable faster, more accurate results for researchers and clinicians.

TEK Optima Research combines cutting-edge hardware development with sophisticated data analytics and AI to deliver a complete imaging platform. We support a wide range of applications, from drug discovery to clinical diagnostics.

Founded in 2019, we’ve quickly established ourselves as a trusted partner for organizations seeking to push the boundaries of microscopic imaging. We currently employ a team of 5 dedicated professionals, operating from our R&D office and manufacturing facility in Dorset and a secondary R&D office in Durham, NC.

Genomics is a pioneering transatlantic TechBio company based in Oxford, UK, specializing in **genomic prevention** and transforming healthcare through the power of genomics.

We leverage large-scale genetic information to provide accurate, personalized risk estimates for common diseases and cancers, enabling early interventions and tailored screening. Our proprietary algorithms and databases link minute variations across the entire genome to biological measurements and disease outcomes, generating population-level insights for healthcare systems and individual-level risk assessments for clinicians.

Genomics partners with leading life sciences and biotech companies, including Novo Nordisk and Vertex, offering a unique approach to sustainable healthcare. Our team of over 150 experts – including world-leading genomic scientists, computational biologists, and data scientists – is dedicated to bringing subject-leading science to a global audience, ultimately transforming lives.

Nicox is an international ophthalmic R&D company, based in Valbonne, France, dedicated to developing innovative therapeutics to help maintain vision and improve ocular health.

We focus on addressing significant unmet needs in glaucoma and ocular allergic conjunctivitis, with a leading program, NCX 470, successfully completing Phase 3 clinical development in the U.S. and China. Our portfolio also includes NCX 1728, a candidate under preclinical evaluation for retinal conditions.

Nicox leverages its proprietary nitric oxide donation research platform and strategic collaborations to advance its pipeline. We are proud to offer commercially available products, VYZULTA® for glaucoma and ZERVIATE® for ocular allergic conjunctivitis, with ZERVIATE also approved for use in China.

Bond Chemicals is a Manchester-based global supplier of fine and speciality chemicals, pharmaceutical intermediates, and raw materials for drug development.

We specialize in sourcing alternative commercial sources and custom synthesis, serving a diverse range of clients in the Life Sciences Industry, including those developing drugs across all phases of development.

Bond Chemicals distinguishes itself through its extensive worldwide network of manufacturing partners, offering a comprehensive product range from grammes to multi-tonnes, coupled with a commitment to quality assurance, competitive pricing, and expert technical support.

Founded in 2003, Bond Chemicals operates from its UK headquarters in Warrington, with additional facilities in Dublin (EU) and New Jersey (US), providing seamless supply chain solutions globally.

RotaChrom Technologies is a Hungarian-based industrial chromatography specialist, delivering silica-free, liquid–liquid CPC purification solutions to the pharmaceutical, biotech, botanicals, nutraceuticals, and cosmetics industries. BR Our core offering – Centrifugal Partition Chromatography (CPC) – bridges the gap between bulk extraction and final polishing, ensuring high yield, reproducibility, and gentle handling of sensitive molecules. We specialize in scalable purification, built to grow with your process from R&D to continuous and full industrial production.

RotaChrom’s technology is built on the principles of liquid-liquid separation and CPC, spanning from benchtop through pilot, continuous to industrial-scale CPC systems, complemented by digital method development tools, solvent handling platforms, and automation solutions. We offer expert-led services to de-risk and accelerate your purification path, including chromatography method development, feasibility studies, and technical transfer support. Our team provides the data-driven insights and scalable strategies needed to accelerate your path to market.

Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 treating patients with multi-drug resistant cancers. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland.

HAYA Therapeutics is a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including cardiovascular disease and cancer. The company is using its innovative cell-state modifying platform to gain novel insights into the biology of long non-coding RNAs (lncRNAs), the ‘dark genomes’ information processing features and ‘source code’. HAYA’s lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting Wisper, which is a tissue and cell-specific cardiac lncRNA known to play a role in heart failure. The company is also developing a pipeline of lncRNA-targeting candidates for the cell-specific treatment of diseases in other tissues, including the lungs and the microenvironment of solid tumor cancers. Headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities at JLABS @ San Diego, HAYA is led by a world-class team of experts in programmable and precision RNA-targeted therapeutics and is supported by a strong investor consortium. HAYA’s mission is to identify and develop breakthrough disease-modifying therapeutics with the potential for greater efficacy, safety, and accessibility than existing treatments.

InFlectis BioScience is a private clinical stage company aiming at targeting and modulating interactions between proteins involved in key human pathophysiological processes. The company is developing small molecule drugs that specifically target the Integrated Stress Response (ISR). Exploiting the ISR’s natural defense offers tremendous potential for the development of a new class of therapies. Led by InFlectis, this area of research is rapidly advancing, resulting in new treatments under development for a variety of disease affecting the central nervous system (CNS), peripheral nervous system (PNS) and inflammation.

BDD Pharma combines drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and create new value-added products. Rapid parallel clinical testing with BDD SWIFT significantly reduces the time from product concept to clinical success. Recognizing that one size does not fit all we specialise in providing responsive, flexible and innovative solutions to our customers. Our patented delayed release technology OralogiK provides unrivalled control of drug release at the right place and time. Our clinical division provides a full clinical package, including protocol development, study documentation design and regulatory authority submission, through to close out and production of ICH GCP-compliant clinical study report. We specialise in gamma scintigraphy, a powerful and versatile technology used to investigate the in vivo behaviour of your formulation. Coupled with pharmacokinetic data, this technique can be used to provide information on time /site of disintegration, gastric emptying, GI transit and intra/ inter individual differences.

iOmx is a young, dynamic start-up in the field of immuno-oncology located in Martinsried/Munich, Germany. Backed by a powerful technology platform and internationally renowned investors, iOmx is driving forward a cutting-edge portfolio of early-stage novel immune-checkpoint drugs through pre-clinical and clinical development. Imprint: https://iomx.com/imprint

Turbine was founded for a simple reason; to understand complex cancers better than existing experimental tools in order to solve unmet oncology needs. Through a multidisciplinary team that unites computer science and molecular biology, and the world's most intricate simulation of cell behavior, we identify treatment options for the 70% of cancers that are currently unexplored. We use our platform, the Simulated Cell™, to uncover novel biological insights across both new and known targets. This allows us to provide a fresh biological context, define responsive patient populations, and design drug combination approaches that diminish resistance. With a process proven by clinical stage predictions and a proprietary pipeline, we continue our mission of unlocking cancer complexity to deliver next-generation precision therapeutics.

AMADIX is a leading molecular diagnostics company focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. The mission of the company is extending people's lives, developing disruptive technologies to detect the tumor years in advance, before the symptoms appear.

aptaTargets is a clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. Our candidates are neuroprotectants and immunomodulators being developed from preclinical stages up to clinical proof-of-concept.

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is based in Lyon, France and Cambridge, MA, USA, and has manufacturing sites in Lyon, France, and Princeton, New Jersey, USA.. ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP).

EUCODIS Bioscience is a leading provider of novel industrial enzymes, with customers in the pharmaceutical, biotechnology, diagnostics, and other industries worldwide. With a portfolio of over 50 enzymes including innovative lipases, beta-lactamases, peroxidases and other enzymes EUCODIS Bioscience has a proven track record of providing customized enzyme solutions. In addition, EUCODIS Bioscience provides services ranging from enzyme engineering to process development as well as protein manufacturing according to our customers' individual specifications. EUCODIS Bioscience provides customized services in recombinant protein and enzyme production by covering the whole spectrum of bioprocess development up to industrial-scale manufacture of your target proteins under ISO9001. Our headquarters and main laboratories are located at the Campus Vienna Biocenter, Austria’s largest Biotech and University cluster.

C4Diagnostics is a French-based biotech specialized in the development of in vitro diagnostic (IVD) tests for human infectious diseases C4Diagnostics' strategy for the better management of Human infectious diseases, is to develop game changing IVD tests which are significantly faster than standard methods whilst maintaining comparable or better performance. Its portfolio currently focuses on the diagnosis of Covid-19 (C4Covid-19), Legionnaires’ Disease (C4Legio LFA), urinary tract infections (C4UTI) and the development of antimicrobial susceptibility tests (C4AST). C4Diagnostics also has a business unit dedicated to environmental diagnostics, called C4Environment. It provides services for the detection of SARS-CoV-2 and other pathogens in the environment (wastewater, air, surface) and has contributed to several Covid-19 surveillance and prevention campaigns since the beginning of the pandemic. With its rapid and highly sensitive IVD tests, C4Diagnostics ambitions to become one of the main actors in the diagnosis of human infectious diseases field, by giving medical labs and healthcare professionals sensible and reliable diagnostic information in a timely manner. The game changing diagnostic solutions developed by C4Diagnostics are a leverage to fight against antibiotic resistance and curb infectious disease epidemics. contact@C4Diagnostics.com

F-star, an invoX company, is a clinical-stage biopharmaceutical business pioneering bispecific antibodies in immunotherapy so more people with cancer can live longer and improved lives. F-star is committed to working towards a future free from cancer and other serious diseases through the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in treatments. F-star has four second-generation immunooncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate, with over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several areas, including oncology, immunology, and CNS.

GQ Bio is pioneering a high-capacity gene therapy vector platform (HCAd) that addresses some of the big challenges in the gene therapy field: Transfer of large and multiple genes with a single vector, highly efficient gene delivery (high transduction efficiency), and large-scale manufacturability. Based on its HCAd vector platform, GQ Bio develops transformative treatments for chronic, prevalent conditions such as osteoarthritis and intervertebral disc degeneration. GQ Bio is headquartered in Hamburg, Germany and has sites at Luckenwalde (greater Berlin area), Germany and Liège, Belgium.

Gesynta Pharma's drug candidate GS-248 is in clinical phase II development for the treatment of endometriosis – a painful, chronic inflammatory disease that affects about 10 percent of women of reproductive age. Endometriosis often leads to severely reduced quality of life and current drug treatments are inadequate for many patients. Gesynta Pharma aims to exploit the full potential of microsomal prostaglandin E synthase-1 (mPGES-1) as a pharmacological target by developing products in areas of unmet medical need where mPGES-1 inhibition provides clear benefits compared to current therapy. The company's next drug candidate, GS-073, is ready to enter clinical phase I in 2023. Gesynta Pharma bases its R&D on research from the Karolinska Institutet. Major shareholders include Industrifonden, Hadean Ventures, Linc, and a number of successful life science entrepreneurs.

NLC - the European Healthtech Venture Builder - is dedicated to advancing health, making it accessible for everyone. By using entrepreneurship at scale, our unique NLC approach allows us to find inventions, and create and support ventures that have the potential to reach the patient. Led by winning teams, together with a dedicated network and driven by data and learnings.

Oryzon Genomics, S.A. is a clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology. Oryzon has a broad and growing portfolio, with two compounds in clinical trials: iadademstat, a highly potent and selective LSD1 inhibitor, in Phase IIa clinical trials for the treatment of acute myeloid leukemia and small cell lung cancer, and vafidemstat, a CNS optimized LSD1 inhibitor in multiple Phase II trials for the treatment of CNS and psychiatric diseases. Phase IIb trials for both compounds are under preparation. Our pipeline also includes ORY-3001, a selective LSD1 inhibitor in preclinical development for the treatment of non-oncological diseases, and additional programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases. Oryzon has been listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). Since then, the company has attracted specialized investors from US, Israel and Europe in several PIPEs led by different US investment banks. The company was founded in 2000 and has offices in Spain and the United States.

Maintaining musculoskeletal health is the keystone of overall health as we get older. As we age our physical condition gradually deteriorates, leading to loss of strength, fitness and mobility. In most cases, this isn’t due to a simple decision to stop exercising. It is due to the breakdown of musculoskeletal function caused by disease. Musculoskeletal diseases such as osteoarthritis, tendinopathy and lower back pain are the primary causes of disability and early retirement in people over the age of 65. Currently, there are no approved disease-modifying drugs for these diseases, meaning that physical decline in old age is inevitable. At Causeway, we believe that physical decline in old age is not inevitable and in indeed may be reversible. To address this, we are developing a range of therapies that treat common MSK diseases that will allow us to remain fit and active into our nineties and beyond. Staying active as we get older also reduces the risk of developing osteoporosis, dementia, diabetes, obesity, cancer and cardiovascular disease. Finding a way to remain fit and active as we age isn’t just a personal imperative but also a global one. By 2050, one in four of us will be over 65 years old, the number of people age over 80 is projected to triple and retirement age to rise to 75-80 years old. As individuals and as a society, we need to find solutions to the problems of ageing. Our goal is to develop therapies that treat the most common MSK diseases, such as osteoarthritis, tendinopathy and lower back pain, re-defining what old age looks and feels like.

Vivasure Medical Ltd. is an ISO 13485 registered medical device company based at Europe’s leading MedTech cluster in Galway, Ireland. Founded in 2009, the company is led by an experienced management team and backed by a syndicate of international venture capital investors and state agencies. The company has developed and patented the world’s first fully absorbable, patch-based closure device specifically designed to seal large-bore arteriotomies in endovascular procedures. Please, refer to our website for further information.

AXELEROS Preclinical Development is a Brussels-based preclinical development consultancy specializing in regulatory affairs and preclinical study management for the biopharmaceutical industry.

We support clients – including biotech companies, SMEs, and research institutions – throughout the entire preclinical process, from initial strategic planning to regulatory submission. Our team provides expert guidance on navigating the complex landscape of global regulations, ensuring your innovations meet the highest standards and accelerate their journey to market.

Our core services encompass a comprehensive suite of offerings, including strategic regulatory planning, global regulatory submissions, sourcing and management of toxicology and pharmacology studies, and toxicological risk assessments. We are dedicated to helping you bring your groundbreaking therapies to patients worldwide. We also offer European Public Affairs support to unlock valuable funding opportunities for your healthcare projects.

EpiXlife is a biotechnology company based in Valencia, Spain, specializing in innovative wellness solutions for healthcare professionals.

We empower professionals across Argentina, Brazil, Colombia, Mexico, Spain, and Uruguay with cutting-edge technologies and personalized training.

EpiXlife distinguishes itself through its integrated approach, combining advanced bioprobes, comprehensive training programs, and targeted marketing strategies, all supported by ongoing expert support. We are dedicated to transforming the wellness industry and helping professionals maximize their impact on patient lives.

Our mission is to provide professionals with the tools and knowledge they need to thrive in a rapidly evolving landscape, fostering a future where wellness is accessible and effective for all.

CNRS UMR8199 is a French research institute based in Lille, specializing in the study of metabolic diseases and their genetic causes.

Our team, led by Pr. Philippe Froguel, focuses on understanding the molecular mechanisms behind diseases like diabetes and obesity, with the ultimate goal of developing more effective prevention and treatment strategies.

We conduct cutting-edge research in genomics and molecular physiology, contributing to a deeper understanding of these complex conditions and paving the way for personalized medicine. We are a key player in the **biotechnology research** sector, collaborating with leading institutions globally.

Established in 1995, CNRS UMR8199 has grown to a team of 11 researchers, furthering our commitment to advancing scientific knowledge and improving patient outcomes.

Orano Med is a French research and development company specializing in the production of high-purity lead-212 (Pb-212), a rare radioactive isotope, and driving innovation in targeted cancer therapies.

Based on a program initiated in 2005, Orano Med has pioneered the targeted alpha therapy (TAT) approach, recognizing and destroying cancer cells while minimizing harm to healthy tissue.

Leveraging Macrocyclics, Inc., a key component of Orano Med, the company operates a robust industrial platform for Pb-212 production and maintains a strong pipeline of research and development, including 18 clinical trials and over 30 patents.

With 220 employees across France and the United States, Orano Med is committed to advancing the field of nuclear medicine and improving patient outcomes through cutting-edge radiotherapeutic solutions.

Q1 Scientific is a Cambrex company, a leading provider of outsourced stability storage and GDP-certified sample management services, operating across Ireland, Belgium, and the United States.

We specialize in supporting pharmaceutical, biotech, and medical device companies with critical stability and GDP storage needs. Our purpose-built, ICH-compliant cGMP facilities offer a secure, reliable, and controlled environment for your valuable samples and products, ensuring data integrity and regulatory compliance.

Q1 Scientific’s 100% on-time pull rate, backup systems, and extensive validation demonstrate our commitment to unparalleled reliability. Partnering with us streamlines your stability programs and contributes to the success of your projects. We offer a range of services including stability storage, photostability testing, thermal cycling, ultra-low freezer storage, and disaster recovery, all within our 15,000+ sample storage spaces spanning -80°C to +50°C.

With 13 years of expertise and a 9.3/10 average customer satisfaction rate, Q1 Scientific is trusted by the world’s top pharmaceutical and medical device companies.

Iktos is a Paris, France-based artificial intelligence company revolutionizing drug discovery.

We specialize in applying generative AI to medicinal chemistry, enabling pharmaceutical companies and research institutions to design and optimize molecules in silico. Our proprietary SaaS platforms, Makya™ and Spaya™, combined with our AI-driven robotics platform, dramatically accelerate the entire drug development process – from initial design to synthesis and testing.

Iktos is at the forefront of innovation, leveraging cutting-edge technology to reduce R&D timelines and increase the success rate of new drug candidates, particularly in oncology and autoimmune diseases. We are proud to have received significant investment and recognition, including a recent EIC Accelerator grant, demonstrating our commitment to transforming the future of drug discovery.

Healx is a mission-driven technology company pioneering the next generation of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are 7,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AI technology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact.

Artios is a leading independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Artios began clinical trials in February 2021 of its small-molecule ATR inhibitor, ART0380, in patients with advanced or metastatic solid tumours. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery and PARP inhibitors; key staff at Artios developed the drug olaparib (Lynparza ™). Artios is building a pipeline of next-generation DDR programmes, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK (CRUK), with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.

Providing predictive analytics from suspended-cells through our unbiased cytometry technology, Cytomos® Dielectric Spectroscopy: CDS™

GH Research is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.

Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of genomic deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for important liver health challenges, from increasing donor liver supply to reducing cirrhosis complications. To learn more, please visit www.ochre-bio.com.

Our goal is to enable the analysis of anything, anywhere, by anyone. We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data. We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society. Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide. Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.

Healx is a mission-driven technology company pioneering the next generation of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are 7,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AI technology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact.

Egetis Therapeutics is a Swedish pharmaceutical company based in Stockholm, specializing in the late-stage development and commercialization of innovative treatments for serious rare diseases.

We focus on addressing significant unmet medical needs within the orphan drug segment, developing therapies like Emcitate® for MCT8 deficiency and Aladote® for paracetamol overdose.

Egetis distinguishes itself through its integrated approach to drug development, combining scientific expertise with a commitment to patient access. Our dedication to bringing life-changing medicines to patients with rare conditions drives our strategic focus and operational excellence.

Founded with a vision to transform patient outcomes, Egetis Therapeutics continues to expand its pipeline and global reach, solidifying its position as a key player in the pharmaceutical industry.

High throughput RNA sequencing, made easy.

Amal Therapeutics is a Biotechnology company located in 64 av., de la Roseraie, 1205 Geneva, Switzerland.

VitalMeds is your trusted community pharmacy Manchester, committed to providing convenient and reliable healthcare support. Location : 802 hyde Road M18 7JD ,Manchester, England. Number :+44 01612077123 Email: info@vitalmeds.co.uk